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The National Agency for Medicines will turn ten years
at the end of February. Looking back, our first decade
has passed quickly in view of the enormous challenges
we faced in the spring of 1993. In this regard the life of
an organisation resembles that of an individual. Ahead
of us looms the great unknown, but every-day life and
its experiences is fast behind us. 
It is important that a sense of realism is present in
the life of organisations. Ten years of medicines’ and
medical devices’ control is merely 1/34 of the total peri-
od of such control in this country. The founding of Col-
legium Medicum in Stockholm in 1663, all of 340 years
ago, can be taken as the starting point. Of course, the
subject matter of medicines control then is hardly com-
parable with that of today.
Has NAM lived up to the expectations leading to its
foundation? I am not competent to answer that ques-
tion, it should rather be put to our clients (refer TABU
6/2002, page 3) and our ‘owners’, i.e. the Ministry of
Social Affairs and Health, playing the role of parent
company governing our business sector.
Whatever mark NAM gets for its performance, two
facts should be borne in mind: We should learn from
the past and face the future without prejudice. I am re-
ferring to strategies, challenges, daring to embark on in-
novations, and questioning the past.  In this regard, the
dynamic medicines’ and medical devices’ industry will
not leave anyone cold. Smaller and bigger changes are
always happening, both at home and in the European
Union. 
Pharmaceutical services in Finland have recently un-
dergone surprisingly extensive and rapid changes.
Generic substitution is the best example of that trend. 
I consider it to be the most significant  pharmaceutical
policy reform in Finland in many decades. Now we
must ensure that this positive reform is properly imple-
mented in practice. Patients, consumers and health care
professionals will evaluate the reform on the basis of
their own experiences. Our task at NAM is to draw up
a list of exchangeable medicinal products, to maintain it
up to date, and to publish it.
Another sudden change was seen in the week preced-
ing Christmas, when the Government decided to pass a
decree allowing pharmacies to give discounts to their
regular customers. This would not be remarkable if our
Parliament had not expressly clarified the Medicines Act
last summer, as far as unified pricing of medicines was
concerned. It is easy to predict that the operating princi-
ples of pharmacies as producers of equal, basic pharma-
ceutical services for all will still have to be reviewed. 
Major reforms of the control of medicinal products
and medical devices within the EU are still pending. To-
gether with the effect of the  enlargement of the EU,
such reforms will have an effect on NAM’s operating
environment. In order for NAM to be able to serve
Finnish interests in promoting the safety of medicines
and medical devices, it should be able to wield more in-
fluence there, where major decisions are made. It is a
question of greater engagement in co-operation in the
European environment. NAM is well equipped to suc-
ceed in that, thanks to the experience and know-how
accumulated during a decade of activity. Ongoing im-
provements in operations, a new organisation, and tak-
ing care of our resources, boost our faith in our future
success.
I should like to thank the customers, associates, in-
terest groups and collaborators of the National Agency
for Medicines for the smooth co-operation and con-
structive feedback during our first 10 years. I should al-
so like to thank the readers of TABU for their interest in
drug information. I take this opportunity to publicly
thank the professional, highly professional  and moti-
vated staff of National Agency for Medicines.
Hannes Wahlroos
DIRECTOR GENERAL
National Agency for Medicines
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The aetiology and pathogenesis of
gout are influenced by both heredi-
tary and environmental factors.
Chronic hyperuricaemia is charac-
teristic of the disease (in men, plas-
ma urate > 420 micromol/l, in
women > 340 micromol/l). Recur-
rent gout attacks are due to further
depositions of urate crystals in the
joint.
Urate is formed as an end prod-
uct of purine metabolism in the
body. Humans receive about a third
of their daily purine supply from
food, two thirds being formed en-
dogenously. In the majority of pri-
mary gout sufferers, hyperuricaemia
is caused by a reduction in the urate
excretion via the kidneys in propor-
tion to the serum urate level. In
about 10% of patients, hyperuri-
caemia is caused by excessive en-
dogenous production of urate (1).
The underlying factors causing in-
creased urate production may in-
clude certain rare genetic enzyme de-
ficiencies, increased cell turnover
(myelo- and lymphoproliferative dis-
eases and haemolytic conditions), in-
creased purine catabolism or in-
creased dietary intake of purines.
About two thirds of the urate is ex-
creted via the kidneys. Uric acid ex-
cretion is reduced by, for instance,
renal insufficiency, acidosis, fasting
and fluid deficiency, hypertension,
hyperparathyroidism and hypothy-
roidism among the endocrinopath-
ies, alcohol, lead, and among drugs
especially by diuretics, ethambutol,
pyrazinamide, levodopa, beta-block-
ers and low dose salicylate (2), and
by ciclosporine (3).
There are good grounds for con-
sidering gout as part of a metabolic
syndrome, the typical features of
which include an excessive amount
of calories in the diet, overweight,
excessive use of alcohol, dyslipidae-
mia and insulin resistance (4,5).
In the majority of patients, gout
sets in first as an acute inflammation
of the metatarsophalangeal joint of
the great toe (podagra), but in about
a fifth of the patients the disease be-
gins polyarticularly. An acute attack
of gout often occurs at night, when
the reduced temperature promotes
the circumstances under which the
precipitation of urate crystals oc-
curs. After an acute attack of gout,
arthritis generally subsides within a
couple of weeks. If hyperuricaemia
is not corrected by change of life
style and/or medication, the attacks
will recur and the patient will exhib-
it tophi, that is, subcutaneous accu-
mulations of deposited urate (6).
The diagnosis of gout is based on
the clinical picture of the disease, on
hyperuricaemia and, above all, on
the detection of urate crystals in the
synovial fluid, or of tophi (7). Even
though hyperuricaemia is found in
almost all gouty patients, its differ-
ential diagnostic value is minimal.
Hyperuricaemia occurs in the gener-
al population more frequently than
gout does. As the serum urate level
arises, however, the risk of an acute
attack of gout increases (8, Table 1).
Radiological changes typical of gout
are not detected in the joints until
the patient has suffered from the
disease for several years.
The treatment of gout is aimed
at focussing effectively on the risk
factors of the disease. The impor-
tance of restricting the intake of
purines, proteins and alcohol has
traditionally been emphasised in di-
etary advice (6, Table 2). The signifi-
cance of weight loss has also been
emphasised in recent years, especial-
ly where there is an associated meta-
bolic syndrome (1). Even on a strict
diet, the urate concentration is usu-
ally only reduced by 100–200 mi-
cromol/l. Asymptomatic hyperuri-
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The diseases gout, calcium pyrophosphate arthropathy (pseudogout) and hydroxyappatitis are all
classed as crystal-induced arthritides. The most commonly occurring one in practice is gout. An
acute attack of gout results from the deposition of urate crystals in the joint. If the methods of
treatment are chosen correctly the patient will recover and remain symptom-free, and it is this,
which makes the diagnosis of gout, and distinguishing it from other forms of arthritis, especially
important. The treatment of the acute stages of gout focuses on relieving the symptoms of the
arthritis. The primary treatment of hyperuricaemia is diet, but the treatment of gout often also re-
quires medical treatment to reduce the level of uric acid.
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caemia is not treated as a rule, but if
the urate level is very high (plasma
urate > 600–700 micromol/l) med-
ical treatment may be indicated.
With co-existent myelo- and lympho-
prolipherative malignancies, it is 
necessary also to treat asymptomatic
hyperuricaemia (9).
Drugs whose mechanisms of effect
vary greatly have been used in med-
ical treatment of gout. Their effect is
based on
•  the reduction of urate production
by xanthine oxidase inhibition (al-
lopurinol)
•  the increase of urate excretion at
the renal level (uricosuric drugs)
•  urate oxidation (rasburicase)
•  the alleviation of symptoms of
acute gouty attacks (colchicine,
NSAID)
Allopurinol
Allopurinol exerts a competitive in-
hibitory effect on the enzyme xan-
thine oxidase and thereby reduces
the urate production in the body. Al-
lipurinol has an active metabolite
which is excreted in the urine, al-
lowing once daily administration of
the drug, but the dose should be de-
creased with co-existing renal insuf-
ficiency (9).
Unlike uricosuric drugs, allopuri-
nol decreases the excretion of uric
acid while correspondingly increas-
ing the urine hypoxanthine and xan-
thine concentrations.  
Rapid changes in plasma urate
concentrations may cause a tenden-
cy to gouty attacks, but allopurinol
therapy will not lead to the forma-
tion of urate crystals or stones in the
urinary tract. Allopurinol is there-
fore the drug of primary choice, es-
pecially when the patient is found to
have urate stones in the urinary
tract, the urate excretion is abun-
dant, or the clinical picture is other-
wise complicated. The effect of al-
lopurinol is also partly based on the
reduction in purine synthesis in the
body. A small initial dose will re-
duce the risk of an acute gouty at-
tack at the beginning of treatment.
Adverse reactions 
The estimated incidence of adverse
reactions of allopurinol reported in
the literature varies greatly among
the different reports (between 5%
and 25%). The most common ones
include mild symptoms of GI tract
irritation, which can be alleviated by
taking the drug at mealtimes. The
most dreaded symptoms, albeit rare,
are hypersensitivity reactions (vary-
ing from mild rash to life-threaten-
ing toxic epidermal necrolysis;
Lyell’s syndrome). Other hypersensi-
tivity reactions include fever, eosino-
philia, elevated hepatic enzymes,
acute interstitial nephritis and exac-
erbation of renal insufficiency (10).
It has also been suggested that hy-
persensitivity occurs three times
more often in patients with renal in-
sufficiency than in other patients (2).
Haematological adverse reactions
include leukopaenia, neutropaenia
and aplastic anaemia. Agranulocyto-
sis is a rare and severe adverse reac-
tion of the treatment. Patients on 
cytostatic therapy, in particular, are
exposed to bone-marrow damage.
A total of 65 adverse reactions
where the suspected primary cause
was allopurinol therapy were report-
ed to the National Agency for Medi-
cines in Finland during 1973–2002
(11, Table 3). The most common ad-
verse reactions were skin reactions,
elevated hepatic enzymes and cyto-
paenia. Two patients were reported
as having the rare Stevens-Johnson
syndrome. Agranulocytosis had oc-
curred in 13 patients. In seven fatal
cases the adverse reaction was
haematological, mainly bone-mar-
row damage and associated occur-
rence of cytopaenia. 
The oxidation-inhibiting effect of
allopurinol, mercaptopurine and
azathioprine deserve particular at-
tention among interactions. The effi-
cacy and toxicity of these drugs are
significantly increased in concurrent
therapy, and the dose is therefore re-
duced to 25% of the normal dose.
Concurrent ampicillin therapy caus-
es a threefold increase in the risk of
skin rash. Allopurinol potentiates
the toxic effects of cyclophosph-
amide.
Probenecid
The effect of probenecid is based on
urate reabsorption inhibition in the
renal tubulae, thereby increasing the
uric acid excretion. Abundant fluid
supply and diuresis must be ensured
during treatment. Urate easily be-
comes precipitated in acid condi-
Table 2.   Diet  for  gouty patients
Very high contents of purines, to be to-
tally avoided
Organ meats
Small fish, shellfish
Yeast
High contents of purines, to be eaten in
small amounts only
Fish
Meat
Beans, peas, asparagus, mushrooms
Low contents of purines, can be eaten
liberally
Cereal products
Milk products
Eggs, fat, sugar (Note: weight loss!)
Fruit
Potatoes, most vegetables
Coffee, tea, cocoa, spices
Fish roe
Other agents with an adverse reaction
Alcohol, especially beer
Acetylsalicylic acid 
Table 1 .  Incidence of  gout  and
plasma urate level  (8)
Incidence Plasma urate
(1/1,000 inh/day) µmol/l)
0.8 < 420
0.9 420–470
4.1 480–530
49 > 540
Table 3.  Adverse react ions
caused by al lopurinol  reported
to the National  Agency for  Medi-
c ines in  F inland during
1973–2002*
65 reports in total
The most common reactions
Skin reactions
Elevated hepatic enzymes
Cytopaenia
Agranulocytosis 13
Rare Stevens-Johnson syndrome 2
Fatal 7
Aplastic anaemia           4
Agranulocytosis and sepsis 2
Thrombocytopenia         1
* The information obtained from
the ADR register of the National
Agency for Medicines cannot be
considered complete in quantity or
quality.
tions; to prevent the development of
kidney stones, urine is alkalised by
giving the patient sodium bicarbon-
ate (3–6 g per day). Probenecid is
generally well tolerated; the most
common adverse reaction is mild
nausea. Rare adverse reactions have
included rash, a rise in temperature
and nephrotic syndrome (10). An in-
teraction which deserves attention is
the inhibiting effect that probenecid
has on the tubular excretion of cer-
tain drugs, the most important drugs
being furosemide, methotrexate, ni-
trofurantoin, zidovudine and several
anti-inflammatories. Probenecid pre-
vents paracetamol conjugation with
glucuronic acid and diminishes its
clearance by half. It is recommended
that the dose of paracetamol be
halved when used together with
probenecid. Probenecid also inhibits
zidovudine glucuronidation and in-
creases the drug plasma concentra-
tion; in concurrent use the dose of
zidovudine should therefore also be
halved. 
Sulphinpyrazone
This drug increases renal excretion
of urate and also has a potent an-
tithrombotic effect. Its effect in pa-
tients with renal insufficiency may
be better than that of probenecid.
Reports of adverse reactions have
included lack of appetite, nausea,
vomiting and abdominal pains. Rare
adverse reactions have included
bone-marrow damage and skin rash
(9,10).
Urate oxidase
By using combination-DNA technol-
ogy, a urate oxidase, rasburicase,
has recently been developed for the
prophylaxis and treatment of hyper-
uricaemia associated with haemato-
logical malignancies. The drug is
strongly uricolytic and the onset of
effect is considerably faster than that
of allopurinol (12). Rasburicase has
so far only been indicated for use at
the start of chemotherapy for malig-
nant blood diseases.
Treatment of acute gout
The treatment of acute gouty attacks
consists of rest, topical cryotherapy
and effective anti-inflammatory ther-
apy. A glucocorticoid injection can
be administered into the joint in
conjunction with diagnostic joint
puncture and synovial fluid aspira-
tion; this usually abates inflamma-
tion of the joint very effectively.
Colchicine
The effect of colchicine is based on
the inhibition of the leucocyte-medi-
ated inflammatory process associat-
ed with acute crystal arthritis. The
drug also has an antimitotic effect.
Colchicine has a potent effect in at-
tenuating acute gouty attacks, but
its use is restricted by uncomfortable
GI tract complications, mainly diar-
rhoea. Intravascular administration
is also a possibility.
Conclusion
Hyperuricaemia is also extremely
common in the Finnish population.
As overweight and other metabolic
syndromes become more frequent in
the population, symptom-free hyper-
uricaemia forms part of an accumu-
lation including several other risk
factors in these patients. Change of
life style and dieting have a benefi-
cial effect on hyperuricaemia as well
as on other risk factors. Asympto-
matic hyperuricaemia is not general-
ly treated with drugs. In the treat-
ment of gout both diet and medica-
tion aim at reducing the urate level
and by doing so also reducing the
risk of recurrent gouty attacks.
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The use of CNS drugs for non-med-
ical purposes is a problem in many
countries. The problem occurs in
Finland as an associated use of nar-
cotics and drugs. There are various
ways of acquiring drugs for misuse.
Compared with the previous year,
the number of break-ins and thefts
in pharmacies and other units in-
creased last year. The number of
forged prescriptions is also suspect-
ed to have increased in recent years.
Illegal importations of drugs prone
to misuse have also caused prob-
lems. A proportion of the drugs
which end up by being misused is
acquired by illegal means, but the le-
gal drug distribution methods also
serve as a channel for misuse, and a
proportion of legally acquired drugs
ends up being misused and sold on
the street. The proportion of CNS
drugs legally prescribed by physi-
cians and ending up in illegal use is
unknown, as also is the size of the
patient group sustaining these oper-
ations.  In order to establish the ex-
tent of the problem and the neces-
sary measures required, a study of
the prescription and non-medical
use of CNS drugs has been carried
out by a working group set up by
the National Board of Medicolegal
Affairs.
The starting point of the study
No national register in Finland  is
maintained with respect to the dis-
pensing of CNS drugs. As the infor-
mation on all the prescriptions and
supplies of CNS drugs is only regis-
tered individually by each pharmacy,
the information has had to be col-
lected in the form of prescription
samples from pharmacies. The study
comprised information from 275
pharmacies in the hospital districts
of Helsinki and Uusimaa, Keski-
Suomi and Varsinais-Suomi covering
the CNS drugs supplied during the
period between 1.5.2001 and
15.6.2001. A total of 170,499 CNS
drug prescriptions were received, by
which drugs were supplied to
110,524 different individuals.
It is difficult to establish the pro-
portion of drugs ending up in non-
medical use on the basis of the in-
formation concerning the prescrip-
tion and supplying of CNS drugs.
The study had established certain
criteria which, when transgressed,
indicated that the individual in ques-
tion belonged to a group at risk of
non-medical use. The condition was
that the individual had during the
study period either received five or
more CNS drug supplies which had
provided him or her with a total of
a minimum of 300 units of a CNS
drug, or that the amount of a CNS
drug received by the individual was
a minimum of 500 units, or that the
patient had received a minimum of
1,500 ml of a cough preparation
containing codeine. It is understood
that the risk group defined in the
study consists not only of problem
users of drugs or narcotics but also
of other individuals, such as patients
with cancer and pain, and of mis-
users on appropriate replacement
and/or withdrawal therapy. The
study is the first of its kind and it re-
veals the extent of the problem of
legally prescribed CNS drugs ending
up for misuse in Finland.
Results
According to the criteria chosen for
this study, the proportion in the
group at risk of non-medical use
was 2.4% of all patients, but they
were supplied with 9.7% of all CNS
drug prescriptions received and
12.9% of the total amount of the
CNS drugs. A proportionate com-
parison of the population of the
three hospital districts under study
with the entire population of Fin-
land enables the researchers to esti-
mate that the group at risk of non-
medical use comprises about 6,600
individuals in the entire country.
This group gets into its possession
about 13% of all CNS drugs pre-
scribed by physicians. A comparison
with all patients showed that the
conspicuous proportions in the risk
group were of male patients in the
age groups of 15–24 years and
25–39 years, and female patients in
the age group of 40–54 years.
The prescription and supply of
CNS drugs to the group at risk of
non-medical use differ in many ways
from other prescription and supply
practices in the overall study materi-
al. It is characteristic of this group
that the CNS drugs are acquired
from several different physicians and
from several different pharmacies.
Over 60% of the individuals in the
risk group were supplied with CNS
drugs prescribed by more than one
physician during the six-week period
under review. According to the
study, this group was supplied with
bigger amounts and more often than
total patient group  with several
concurrent sedatives, analgesics con-
taining codeine and hypnotics with
long-term effect.
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The risk group also received mi-
dazolam and temazepam more fre-
quently than others. The suspicion
of possible misuse of a cough prepa-
ration containing codeine was fo-
cused on a couple of individual pa-
tients. The package sizes and drug
quantities prescribed also differed
between the groups. According to
the study, the group at risk of non-
medical use was on average pre-
scribed larger packet sizes of CNS
drugs and higher quantities than the
overall group studied.  The highest
total quantities prescribed by differ-
ent physicians and supplied to a sin-
gle patient amounted to about 40
tablets of opioids and about 60
tablets of hypnotics per day.
Surprisingly, the study revealed
that sickness insurance benefit was
paid out for drugs supplied to the
group at risk of misuse almost as of-
ten as for the CNS drugs supplied to
the entire group. 
The study material showed that
the majority of CNS drugs for the
group at risk of non-medical use
were prescribed by non-specialists
(61% of the prescriptions); 23% by
other than psychiatrists and 14% by
psychiatrists. Interns and dentists
wrote a couple of percent of the
CNS drug prescriptions. There is
hardly any difference in this distrib-
ution in the study material overall.
The study also discussed the signifi-
cance of the years of service of the
prescribing physicians in the pre-
scribing of CNS drugs. A propor-
tionately larger quantity (12%) of
the CNS prescriptions written by
physicians with a greater number of
years of service were supplied to the
risk group for non-medical use than
by physicians with fewer years of
service (9%). “Middle-aged” physi-
cians, by their years of service, were
placed between these two groups.
The study did not go into details
about the physicians’ offices, i.e.
whether they fell within the public
or the private sector.
The study results show that the
majority of CNS drugs are pre-
scribed and supplied for the purpose
of medically justified and appropri-
ate treatment. The study neverthe-
less confirmed unequivocally that
obtaining drugs for misuse by de-
ceiving the physicians, and picking
them up from several different phar-
macies, is easy.
Proposals of the Finnish Working Group for the measures by which it would
be possible to prevent CNS drugs from being acquired for misuse and street
sales.
•  It would be important to establish and review the exchange of information
between the physician and the pharmacy in order to prevent the above
problem.  This could be arranged primarily with the patient’s consent. 
•  It should be possible to increase the exchange of information even without
the patient’s consent where the physician or the pharmacy has a strong
reason to suspect misuse.  When drugs are collected from the pharmacy
for misuse or for selling on the street, it is justified to doubt whether it is
any longer a question of relationship to treatment and whether the protec-
tion of privacy continues to serve the needs of the patient.  In situations
where suspicion of misuse is justified, the physicians and the pharmacies
should by law be provided with the opportunity to obtain details of the
drugs supplied to the individual in question.
•  Since the study showed that sickness insurance benefit was paid to patients
of the group at risk of missuse as frequently as to other groups of patients,
the benefits of the information collected thereby should be made more
readily available. Finnish regulations about secrecy ought not to prevent
the Social Insurance Institution from being able to provide details of drug
purchases to the prescribing physician, if the insured individual, despite a
warning, continues to buy more drugs than necessary for the treatment of
his or her ailment. By increasingly using the benefit of this procedure, the
physicians could obtain information about patients whose prescriptions
end up being used for anything else but treating their illnesses.
•  The number of forged prescriptions and false information given in com-
puted prescriptions has increased in recent years. Pharmacies should focus
increasingly on confirming the accuracy and genuineness of prescriptions
when dealing with CNS drugs. In unclear situations the information
should always be checked with the physician. Physicians can also prevent
prescription forgeries by reviewing their prescription practices. Clear, legi-
ble notes and a proper signature – not merely initials or a cross – and the
use of a stamp will make forgery more difficult and increase the possibility
of detection of forgeries and other incongruities at the pharmacy.
•  Due to forgeries occurring, telephoned prescriptions of CNS drugs should,
for example, be restricted to the smallest package size. When the regula-
tion on drug prescriptions comes to be renewed, the complexities associat-
ed with CNS drugs established by this study should be taken into account.
Issuing a treatment recommendation for CNS drug prescriptions and ther-
apeutic use would also be advantageous at the present time. 
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Summary 
These consumption data are based
on the sales statistics for drugs com-
piled by the National Agency for
Medicines from the drug sales of
wholesalers to pharmacies. As
Finnish pharmacies have a fast
turnover of stocks (1), the sales fig-
ures of wholesalers can be assumed
to reveal which OTC drugs the con-
sumers buy from pharmacies.The
sales of OTC drugs for outpatient
use by pharmacies are reviewed  in a
style similar to that of Finnish Sta-
tistics on Medicines (2). The drugs
are listed according to ATC Codes
(Table). The group of preparations
used for common ‘flu-like symptoms
contains cough, cold and throat
preparations. The cold preparations
include combination preparations
indicated for the treatment of com-
mon ‘flu-like symptoms and they
contain e.g. acetylsalicylic acid or
opium alkaloids or their derivatives.
The group titled “Other” is the
largest and most varied one, con-
taining, for instance, several topical
preparations and eye and ear drops
also available as OTC drugs.
The defined daily doses
(DDD/1,000 inhab. /day) are used as
a means of calculation to assess the
consumption of OTC drugs (Fig. 1).
Not all drugs, however, can be as-
signed a DDD, owing to the varia-
tion in the doses used, e.g. dermato-
logical preparations, vitamins and
minerals. In these instances, a sec-
ond means of calculation used is the
cost (retail prices in Euros) (Fig. 2).
On examining the figures it must be
borne in mind nevertheless that the
amount of the cost varies according
to the health care price index (2).
Development of sales
The sales of prescription and OTC
drugs by pharmacies in Finland in
2001 based on retail prices totalled
EUR 1,587 million. The proportion
of OTC preparations came to about
EUR 251 million, i.e. 15.8%. In
1996, the sales of drugs in outpa-
tient care amounted to EUR 1,110
million, of which the OTC drug
proportion was about EUR 226 mil-
lion (20.4%). The sales of OTC
drugs by pharmacies have conse-
quently increased to some extent,
but their share of the total sales has
shrunk  (2).
The sales of OTC drugs were at
their lowest in 1998. Since then, the
sales increased and have grown by
3–6.5%.
Drugs for GI disorders
Drugs for GI disorders were, as de-
fined daily doses, the biggest group
of OTC drugs used in 1996–2001
(Fig. 1). Their use continued to
grow somewhat at the start of the
century. The OTC consumption of
these drugs in 2001 mounted to
36.6 DDD/1,000 inh./day (Fig. 1).
This amount was divided between
the consumption of laxatives, 75%,
antacids  and H2-receptor blockers
15%, and the rest, antidiarrhoeals,
digestives and antiflatulents, 10%
(2).
Measured by cost, the drug
group for GI disorders remained in
third or fourth place over an entire
period of six years (Fig. 2). The
most commonly used drugs, laxa-
tives, are relatively cheap.
Analgesics
Analgesics had the second highest
OTC consumption figures, measured
as DDD, in 1996–2001 (Fig. 1). In
2001 the consumption reached 26.9
DDD/1,000 inhab./day (2).
Combination analgesics are being
replaced by the use of preparations
containing only a single medicinal
substance (3). In 1996–2001 the
highest increase in OTC consump-
tion was of ibuprofen (2). The con-
sumption of paracetamol has in-
creased only slightly, whereas the
consumption of acetylsalicylic acid
and that of ketoprofen have dimin-
ished (2). Analysis of consumption
shows that changing the prescription
status of analgesics from POM to
OTC appears to decrease the pre-
scription sales of the drug temporar-
ily without necessarily increasing its
OTC consumption (3).
In money terms, the analgesics
group has shown the highest OTC
sales figures ever since 1997 (Fig. 2).
The sales of analgesics increased by
about 14% during the review peri-
od. In 2001, they were bought for
self-treatment purposes at a total
cost of over EUR 51 million, which
is about a fifth of all OTC sales (2).
Drugs for common ‘flu-like
symptoms and topical deconges-
tants
The third biggest OTC consumption
occurred in the group of drugs used
to treat common ‘flu-like symptoms
(Fig. 1). The OTC consumption of
cough preparations in 2001 amount-
Consumption of OTC drugs in Finland during
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ed to 7.2 DDD/1,000 inh./day (2);
43% of these were expectorants,
36% were cough suppressants and
21% were combinations of these.
Expectorants were thus used most of
all, even though doubts have been
expressed about whether their use
for self-treatment is necessary.
Preparations containing bromhexin
were purchased most of all (44% of
the total consumption of expecto-
rants). Over a third (33%) of all ex-
pectorants purchased in 2001 were
older preparations of guaiphenesin
and combination preparations. The
proportion of expectorants contain-
ing carbocisteine or acetylcysteine
was 23%.
The consumption and sales of
throat preparations have also been
steady. The use of throat tablets
containing antiseptics (dichloroben-
zyl alcohol and chlorhexidine) was
about as great as that of prepara-
tions containing antibiotics (grami-
cidin). Last year, 53% of the throat
preparations used were drugs con-
taining antiseptics and 45% of them
contained antibiotics.
Topical decongestants were the
fourth largest group of drugs used
(sympathomimetics, antiallergic
agents and corticosteroids) (Fig. 1).
The OTC consumption has remain-
ed steady for the past few years and
totalled 8.4 DDD/1,000 inh./day in
2001 (2). The total cost of topical
decongestants purchased last year
was about EUR 5.4 million, whereas
the sales of cough preparations
reached well over EUR 13 million
(2).
Antiallergic agents
The OTC consumption of antialler-
gic agents has also been steady and
reached 4.3 DDD/1,000 inh./day in
2001. For the past few years the
consumption has somewhat in-
creased, as the more recent, so-
called third generation antihista-
mines became OTC drugs. The con-
sumption in 2001 was, in fact, al-
most double that of 1996. Year
2001, the consumption of systemic
antihistamines sold as prescription
drugs in outpatient care totalled
19.3 DDD/1,000 inhab./day; their
OTC consumption was 2.9
DDD/1,000 inhab./day. Approxi-
mately 15% of systemic antihista-
OTC groups
Analgesics
Drugs containing one medicinal substance
- ibuprofen
- paracetamol 
- acetylsalicylic acid 
- ketoprofen
Combination preparations
- acetylsalicylic compounds
- compounds of paracetamol 
- compounds of phenazone (until 1998)
Vitamins and minerals 
Vitamins
Iron preparations
Calcium preparations
Drugs for GI disorders
Laxatives
Antacids, sucralfate and H2 receptorblockers
Antidiarrhoeals
Digestives, including enzymes
Antiflatulents
Drugs for ’f lu-l ike symptoms
Cough preparations
Expectorants
Cough suppressants
Compounds of cough suppressants and expectorants 
Cold preparations
Throat preparations    
Dermatologicals
Corticosteroids used for skin treatment
Topical antifungals
Antivirals
Topical antibiotics
Anti-acne preparations
Other
Nicotine (including chewing-gums, patches etc.)
Antiallergics
Cetirizine 
Loratadine 
Sodium cromoglicate 
Acrivastine 
Beclomethasone 
Levocabastine    
Topical preparations for joint and muscular pain 
Topical decongestants 
Other
ATC-code
M01AE01
N02BE01
N02BA01
M01AE03
N02BA51
N02BE51
N02BB51
A11
B03A
A12A
A06
A02 
A07
A09
A02D, A03AX
R05C
R05D
R05F
R02
D07
D01A
D06B
D06A
D10
N07BA01
R06AE07
R06AX13
S01GX01, R01AC01
R06AX18
R01AD01
R01AC02
M02A
R01A
Fig. 1.  Phar-
macy sales
of OTC
drugs
(DDD/1,000
inh/day).
Source: the
National
Agency for
Medicines,
drug sales
register.
Drugs for GI disorders
TABU 1.2003 43
mines used in outpatient care are in-
deed bought over the counter. The
antiallergic agent reaching the high-
est OTC sales figures during
1996–2001 was cetirizine (2).
Nicotine
Nicotine preparations used as anti-
smoking agents have also been sold
very steadily (Fig. 1). Year 2001
their sales reached over EUR 16 mil-
lion, giving the group the sixth high-
est position in drug sales overall
(Fig. 2). The sales have increased by
33% since 1996. 86% of the nico-
tine preparations sold were chewing-
gums.
Vitamins and minerals
In money terms, the majority of
OTC sales in 1996 were of vitamins
and minerals (Fig. 2). OTC sales of
these preparations have since de-
creased by 13%. On one hand, the
consumption may have been influ-
enced by studies published in the
mid 1990s where risks associated
with vitamin supplements were dis-
cussed (4). On the other hand, the
decrease in OTC sales does not nec-
essarily reveal a reduction in their
use, since preparations similar to vit-
amins and minerals may also be
purchased from health food shops.
Drugs of this group were pur-
chased to the value of EUR 39 mil-
lion in 2001, which makes the
group the second largest, immediate-
ly after the group of analgesics (Fig.
2).
Dermatologicals and topical
drugs for joint and muscular pain
The consumption of dermatologicals
has remained very steady and has
been the fifth largest group in mon-
ey terms during 1996–2001 (Fig. 2).
The majority of OTC preparations
sold were topical corticosteroids. In
2001 their OTC sales in outpatient
care at retail prices reached over
EUR 8 million. 
Topical preparations for joint
and muscular pain were purchased
at a total cost of less than EUR 7.8
million. OTC sales of salicylic acid
containing ointments reached over
9,000 g/1,000 inhabitants during
year 2001 (2).
Conclusion
There were no major changes in the
OTC consumption and sales of
drugs during 1996–2001. Drugs for
GI diseases and analgesics attained
the highest OTC sales, measured in
DDD. Measured in money, the list
was topped by analgesics, vitamins
and minerals.
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Fig. 1.  Pharmacy sales of OTC drugs (in Euros). Source: the National Agency for Medicines, drug sales register.
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Survey on TABU 2002
More of everything! 
A telephone survey by Otanta-
tutkimus Oy Finland was made to
assess the significance of TABU
Journal as compared to other pro-
ducers/journals of drug information.
The questions were addressed to
255 physicians and 80 pharmacists. 
The physicians interviewed were
first asked what sources of drug in-
formation did they remember and
how they evaluated the information
from various sources. TABU ob-
tained a good overall score with the
remark, however, that the practicali-
ty of the articles could be improved
(Fig 1).  
The physicians were also asked
which producers of drug informa-
tion could potentially influence their
drug prescription practices. The im-
pact of information from the drug
industry was estimated less impor-
tant and correspondingly, that from
the National Agency of Medicines
more important compared to the
survey two years ago (Fig 2).   
The final question ”What topics
should TABU cover in the future?”
revealed a seemingly insatiable need
for information, especially concern-
ing new drugs and adverse drug re-
actions – the authentic answer quot-
ed in the title speaks for itself. 
Fig.  1 .  Your opinion of  TABU/Finnish Medical  Journal /Duodecim
on the scale  4–10?
Fig.  2.  Does information from any source inf luence your 
prescr ipt ion habits?  Which source?
